References
- Dahl O, Horn A, Morild I, et al. Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Results of a randomized multicenter trial in Western Norway. Cancer. 1990;66(11):2286–2294.
- Gerard A, Buyse M, Nordlinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the european organization for research and treatment of cancer (EORTC). Ann Surg. 1988;208(5):606–614.
- Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systemic overview of 8507 patients from 22 randomised trials. Lancet Oncol. 2001; 358:1291–1304.
- Cedermark B, Dahlberg M, et al.; Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980–987.
- Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479–1482.
- Guren MG, Korner H, Pfeffer F, et al. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. Acta Oncol. 2015;54(10):1714–1722.
- Wibe A, Rendedal PR, Svensson E, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg. 2002;89(3):327–334.
- Glimelius B, Beets-Tan R, Blomqvist L, et al. Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol. 2011;29(16):2142–2143.
- Mercury Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. Br Med J. 2006;333(7572):1–6.
- Fokas E, Glynne-Jones R, Appelt A, et al. Outcome measures in multimodal rectal cancer trials. Lancet Oncol. 2020;21(5):e252–e264.
- Glynne-Jones R, Hughes R. Critical appraisal of the 'wait and see' approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg. 2012;99(7):897–909.
- Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–717. discussion 717–718.
- Habr-Gama A, Sao Juliao GP, Fernandez LM, et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think!. Dis Colon Rectum. 2019;62(7):802–808.
- Pietrzak L, Cencelewicz A, Rutkowski A, et al. The utility of short-course radiotherapy in watch-and-wait strategy for rectal cancer. Post hoc analysis of two prospective studies. Acta Oncol. 2022.
- Hammarstrom K, Imam I, Mezheyeuski A, et al. A comprehensive evaluation of associations between routinely collected staging information and the response to (chemo)radiotherapy in rectal cancer. Cancers. 2020;13(1):16.
- Imam I, Hammarstrom K, Sjoblom T, et al. Neoadjuvant rectal (NAR) score: value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery? Radiother Oncol. 2021; 157:70–77.
- Rombouts AJM, Hugen N, Verhoeven RHA, et al. Tumor response after long interval comparing 5x5Gy radiation therapy with chemoradiation therapy in rectal cancer patients. Eur J Surg Oncol. 2018;44(7):1018–1024.
- Fokas E, Appelt A, Glynne-Jones R, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021;18(12):805–816.
- Hughes R, Glynne-Jones R, Grainger J, et al. Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? Int J Colorectal Dis. 2006;21(1):11–17.
- Bahadoer RR, Dijkstra EA, van Etten B, RAPIDO orative investigators, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42.
- Cho MS, Park YY, Yoon J, et al. MRI-based EMVI positivity predicts systemic recurrence in rectal cancer patients with a good tumor response to chemoradiotherapy followed by surgery. J Surg Oncol. 2018;117(8):1823–1832.
- Lee ES, Kim MJ, Park SC, et al. Magnetic resonance imaging-detected extramural venous invasion in rectal cancer before and after preoperative chemoradiotherapy: diagnostic performance and prognostic significance. Eur Radiol. 2018;28(2):496–505.
- Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54(6):295–308.
- Siddiqui MRS, Simillis C, Bhoday J, et al. A Meta-analysis assessing the survival implications of subclassifying T3 rectal tumours. Eur J Cancer. 2018; 104:47–61.
- Hughes R, Harrison M, Glynne-Jones R. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy? Acta Oncol. 2010;49(3):378–381.